Chuyển sang chế độ ngoại tuyến với ứng dụng Player FM !
Once Weekly Basal Insulin
Manage episode 398174623 series 2931422
Insulin icodec is the first class of long-acting insulin to be administered only once a week. Join host, Jen Moulton, as she discusses the safety and efficacy of insulin icodec with guest, Geoff Wall.
The GameChanger
Insulin icodec is the first of the ultra long-acting insulins with once weekly dosing. Multiple clinical studies have suggested these pharmacokinetics work. A new meta-analysis suggests that insulin icodec is more effective than other basal insulins and at least as safe concerning hypoglycemia.
Jen Moulton, RPh
President + Founder
CEimpact
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Wang P, Zhang Y, Xu W, et al. Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Diabetol Metab Syndr. 2024 Jan 3;16(1):3. doi: 10.1186/s13098-023-01240-5. PMID: 38172995; PMCID: PMC10763463.
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01240-5#Sec19
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the chemical and structural changes that make icodec different from other basal insulins
2. Discuss the results of the meta-analysis about insulin icodec
0.05 CEU/0.5 Hr
UAN: 0107-0000-24-043-H01-P
Initial release date: 1/29/2024
Expiration date: 1/29/2025
Additional CPE details can be found here.
274 tập
Manage episode 398174623 series 2931422
Insulin icodec is the first class of long-acting insulin to be administered only once a week. Join host, Jen Moulton, as she discusses the safety and efficacy of insulin icodec with guest, Geoff Wall.
The GameChanger
Insulin icodec is the first of the ultra long-acting insulins with once weekly dosing. Multiple clinical studies have suggested these pharmacokinetics work. A new meta-analysis suggests that insulin icodec is more effective than other basal insulins and at least as safe concerning hypoglycemia.
Jen Moulton, RPh
President + Founder
CEimpact
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Wang P, Zhang Y, Xu W, et al. Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Diabetol Metab Syndr. 2024 Jan 3;16(1):3. doi: 10.1186/s13098-023-01240-5. PMID: 38172995; PMCID: PMC10763463.
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01240-5#Sec19
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the chemical and structural changes that make icodec different from other basal insulins
2. Discuss the results of the meta-analysis about insulin icodec
0.05 CEU/0.5 Hr
UAN: 0107-0000-24-043-H01-P
Initial release date: 1/29/2024
Expiration date: 1/29/2025
Additional CPE details can be found here.
274 tập
Tất cả các tập
×Chào mừng bạn đến với Player FM!
Player FM đang quét trang web để tìm các podcast chất lượng cao cho bạn thưởng thức ngay bây giờ. Đây là ứng dụng podcast tốt nhất và hoạt động trên Android, iPhone và web. Đăng ký để đồng bộ các theo dõi trên tất cả thiết bị.